Emcure Pharma IPO

Emcure Pharmaceuticals Ltd

₹13,440 /14 sharesMinimum Investment

Emcure Pharma IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
BSE₹1,008.00₹1,325.05₹317.05 (31.45%)

Emcure Pharma IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
3 Jul ‘24 - 5 Jul ‘24₹13,44014₹960 - ₹1,008
Issue SizeIPO Doc
1952.03Cr
RHP PDF

Subscription rate

As of 05 Jul'24, 05:00 PM
Qualified Institutional Buyers195.83x
Non-Institutional Investor48.19x
Retail Individual Investor6.92x
Employees8.56x
Total67.69x

About the company

Emcure Pharmaceuticals, based in India, is involved in the development, manufacturing, and global marketing of pharmaceutical products spanning various therapeutic areas. The company has a product portfolio consisting of orals, injectables, and biotherapeutics. Emcure's products reach over 70 countries worldwide. The company operates 13 manufacturing facilities throughout India, equipped to produce pharmaceutical and biopharmaceutical products. These facilities handle dosage forms, including oral solids, oral liquids, and injectables—both liposomal and lyophilised. They manufacture biotherapeutics and complex active pharmaceutical ingredients (APIs), such as chiral molecules, iron molecules, and cytotoxic products.;
Founded in
1981
Managing director
Mr. Satish Ramanlal Mehta
Parent organisation
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd IPO
https://www.youtube.com/watch?v=nRutVwVpTCI

Strength and risks

Strengths
Risks
Emcure Pharmaceuticals has expanded its presence in both the retail and hospital sectors, significantly increasing its product offerings. Since acquiring Tillomed Laboratories in the financial year 2014, the company has grown its product range from just two to more than 150 by September 30, 2023.
In Canada, Emcure has enhanced its market position through the expansion of its portfolio of generic and differentiated products. Additionally, in November 2023, Marcan, a subsidiary of Emcure, acquired a majority stake in Mantra Pharma Inc., a Canadian company specialising in the sale and distribution of pharmaceutical finished formulation products, natural health products, and medical devices, primarily within Quebec.
The company has seen a steady increase in its revenue from operations, climbing from Rs 5,033.47 crore in FY21 to Rs 5,855.39 crore in FY22 to Rs 5,985.81 crore in FY23.
Emcure Pharmaceuticals markets its diverse product portfolio in over 70 countries, with Europe and Canada serving as its primary international markets. For the six months ending September 30, 2023, and the financial year 2023, international sales accounted for 49.16% and 46.84% of total revenue from operations, respectively.
The company operates 13 manufacturing facilities located in Maharashtra, Gujarat, Sikkim, and Karnataka, as well as in the Union Territory of Jammu and Kashmir.

Financials

*All values are in Rs. Cr
No Graph Data To Display

Application details

Apply asPrice bandApply upto
Regular960 - 1008₹2 Lakh
Employee870 - 918₹2 Lakh
High Networth Individual960 - 1008₹2 - 5 Lakh
For Emcure Pharma IPO, eligible investors can apply as Regular & Employee.
ⓒ 2016-2024 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 5.1.7
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  IDFC |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ

ABOUT GROWW